Drug Approval | April 12, 2023
Zydus receives final approval from USFDA for Tavaborole Topical Solution
Tavaborole Topical Solution, 5% had annual sales of US $3.1 million in the United States
Tavaborole Topical Solution, 5% had annual sales of US $3.1 million in the United States
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.
To enable company to be future-ready by tapping potential in CDMO space
Azithromycin Tablets USP, 500 mg had annual sales of US $20 million in the United States
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Bourgoin early development hub broadens offerings for oral solid dose formulations
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Subscribe To Our Newsletter & Stay Updated
